구조모아 (StructureMoa)항암 chemical structure spider web
방문Beijing Geekgene Technology Co.LTD
TCR-T cells(Beijing Geekgene Technology Co., LTD)은 Colorectal Cancer 표적 세포·유전자 치료로, Colorectal Cancer; Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: bispecific molecule and αPRAME 425 TCR T-cells each exhibited potent, T-cell mediated cytotoxicity against PRAME + NUT carcinoma cells. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 4% (ClinicalTrials.gov NCT03816332). 차별점: novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Colorectal Cancer
Colorectal Cancer; Lung Cancer
Active
2026-09-02
Data Confidence · Medium
Development Signal · Watch
NK cell recognition via the "missing-self" response
retrovirally transduced to express KRAS G12D-targeting TCRs, and expanded for 10 days in t
humanized patient-derived xenograft model of Claudin18
novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β
bispecific molecule and αPRAME 425 TCR T-cells each exhibited potent, T-cell mediated cytotoxicity against PRAME + NUT carcinoma cells
T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation
apoptosis through coordinated granzyme/perforin and Fas/FasL signaling, enabling rapid cytotoxic elimination of multiple tumor ta
biomarker to enrich tumor-reactive CD8⁺ TILs and to improve adoptive cell transfer strategies in futur
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
구조화 데이터
xenograft (PDX) model
rat
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Beijing Geekgene Technology Co.LTD
TCR-T cells(Beijing Geekgene Technology Co., LTD)은 Colorectal Cancer 표적 세포·유전자 치료로, Colorectal Cancer; Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: bispecific molecule and αPRAME 425 TCR T-cells each exhibited potent, T-cell mediated cytotoxicity against PRAME + NUT carcinoma cells. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 4% (ClinicalTrials.gov NCT03816332). 차별점: novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Colorectal Cancer
Colorectal Cancer; Lung Cancer
Active
2026-09-02
Data Confidence · Medium
Development Signal · Watch
NK cell recognition via the "missing-self" response
retrovirally transduced to express KRAS G12D-targeting TCRs, and expanded for 10 days in t
humanized patient-derived xenograft model of Claudin18
novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β
bispecific molecule and αPRAME 425 TCR T-cells each exhibited potent, T-cell mediated cytotoxicity against PRAME + NUT carcinoma cells
T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation
apoptosis through coordinated granzyme/perforin and Fas/FasL signaling, enabling rapid cytotoxic elimination of multiple tumor ta
biomarker to enrich tumor-reactive CD8⁺ TILs and to improve adoptive cell transfer strategies in futur
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
구조화 데이터
xenograft (PDX) model
rat
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.